Equity Overview
Price & Market Data
Price: $0.541
Daily Change: -$0.0301 / 5.56%
Daily Range: $0.54 - $0.571
Market Cap: $3,560,532
Daily Volume: 130,526
Performance Metrics
1 Week: -11.17%
1 Month: -33.60%
3 Months: -50.37%
6 Months: -62.17%
1 Year: -78.78%
YTD: -27.91%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.